Please login to the form below

Not currently logged in
Email:
Password:

Pharmacoepidemiology standards published

The European Medicines Agency and the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance have published guidance on methodological standards in studying the effects of drugs in large groups of people

The European Medicines Agency (EMA) and the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) have published guidance on methodological standards in pharmacoepidemiology – the study of the effects of drugs in large groups of people.

The guidance gives reviews and access to the existing methodological guidance for research in pharmacoepidemiology and pharmacovigilance, with information on study designs and methods.

These are based on internationally agreed recommendations and key points from important guidelines, published articles and textbooks.

In a statement, agencies said: "The intention of the guide is not to duplicate the text from existing guidance but rather to offer the researcher a single overview document and web resource including an overview of the relevant recommendations."

The ENCePP is an EMA project to strengthen the post-approval monitoring of medicinal products in Europe by facilitating studies focusing on the safety and benefit-to-risk ratio of marketed drugs.

A dedicated ENCePP working group consisting of experts in pharmacoepidemiological and pharmacovigilance research developed the guide, with the final publication developed following a public consultation.

The EMA has the guide available for download (PDF).

2nd June 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics